About Charm Therapeutics
CHARM Therapeutics is a biotechnology company focused on delivering transformational medicines through advanced understanding of protein-ligand interactions. Founded by leaders with proven track records in AI and drug discovery, CHARM is developing a next-generation menin inhibitor for the treatment of Acute Myeloid Leukemia (AML). Unlike traditional AML therapies that attempt to kill leukemic cells, CHARM's approach focuses on reprogramming them by preventing the interaction that keeps them cancerous. The company has designed structurally optimized inhibitors that are highly potent and bind precisely within the KMT2A interface on menin. CHARM's best-in-class menin inhibitor is specifically engineered to address resistance mechanisms observed with first-generation menin approaches, with the goal of delivering durable treatment outcomes to AML patients. The company is advancing its lead candidate into clinical trials, leveraging AI-driven drug discovery capabilities to transform patient outcomes in hematologic malignancies.
Mission & Story
Mission
We are delivering transformational medicines through the understanding of protein-ligand interactions
Founding Story
Founded by leaders with a track record in AI and drug discovery
Clinical Focus
Medical conditions and clinical areas addressed by Charm Therapeutics.
Who It Serves
Milestones & Awards
Recent Milestones
Advancing next generation menin inhibitor into clinical trials
Company Details
- Headquarters
- London, England, United Kingdom
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.